Aligos Therapeutics Inc (ALGS) Stock Price, Quote & News

Company Profile

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-12575...

Industry: Biotechnology

Sector: Healthcare

Phone: 800-466-6059

Website: www.aligos.com

Address:

One Corporate Drive, 2nd Floor, South San Francisco, United States

Buyhighsellatlow Jul. 31 at 5:55 PM

If you believe in the potential for $ALGS here at the 50 day is a good add for me.

1 · Reply

Buyhighsellatlow Jul. 30 at 12:57 AM

$ALGS Lost almost $1K on this today. 6M shares outstanding, 62% owned by institutions, 130m cash, 55M mkt cap, enough until mid-2026, phase 2 drugs, collaboration deal with $MRK 🤦

0 · Reply

beeny Jul. 26 at 3:37 PM

$ALGS doubled it you bought around the low👈👀

0 · Reply

Buyhighsellatlow Jul. 24 at 5:09 PM

$ALGS

0 · Reply

Quantumup Jul. 22 at 12:10 PM

Citizens reiterated $MDGL Mkt OP/$470 after its 2Q25 survey showed a 46% prescription rate for Rezdiffra (up from 42% in its 1Q survey)" $IVA $AKRO $ALGS $VKTX ETNB SGMT LLY #MASH Citizens in its note to investors said, "Our 2Q25 survey shows a 46% prescription rate for Rezdiffra (up from 42% in our 1Q survey), with ~60% of patients on paid drug and consistent high persistence; we reiterate our Market Outperform rating and $470 risk-adjusted, DCF-derived price target on Madrigal Pharmaceuticals. Most metrics in our 2Q25 physician survey improved from 1Q, which is a good sign coming out of the typical 1Q reimbursement dynamics. Citizens additionally said:

0 · Reply

beeny Jul. 17 at 2:30 PM

$ALGS this second half will be vertical ⬆️

0 · Reply

Paddy444 Jul. 17 at 2:11 PM

$ALGS

0 · Reply

Bojack_money Jul. 17 at 1:05 PM

$ALGS Higher highs, higher lows...something something making money.

0 · Reply

HedgeUrHedge Jul. 10 at 4:27 PM

$ALGS eventually whales need to realize value comes from results and an edge of reimbursement cardio metabolic benefits, lower dosage, higher Pk and ORAL drugs! Patients don't want to be taking injections every week!

2 · Reply

HedgeUrHedge Jul. 10 at 4:22 PM

$ALGS i don't see why this shouldn't be at minimum 500M market cap as of today if we are looking at other MASH and HBV small cap competitors strictly on phase 2/3 results. What has other MASH small cap competition achieved exactly to be at a billion market cap? None of which has approved MASH drugs, other than Madrigal, which is actually making money today and is going to breakeven/make a profit until 2027.

1 · Reply

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025

Jul 11, 2025, 8:30 AM EDT - 20 days ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 18, 2025, 8:00 AM EDT - 6 weeks ago

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

May 29, 2025, 8:00 AM EDT - 2 months ago

Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:00 AM EDT - 2 months ago

Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal

May 8, 2025, 8:00 AM EDT - 3 months ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

May 6, 2025, 8:00 AM EDT - 3 months ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Apr 29, 2025, 8:30 AM EDT - 3 months ago

Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025

Apr 23, 2025, 4:05 PM EDT - 3 months ago

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

Mar 26, 2025, 8:00 AM EDT - 4 months ago

Aligos Therapeutics Presents Positive Data at APASL 2025

Mar 10, 2025, 8:00 AM EDT - 5 months ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 5 months ago

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

Feb 12, 2025, 7:00 AM EST - 6 months ago

Aligos Therapeutics Announces $105 Million Private Placement Financing

Nov 19, 2024, 1:30 PM EST - 9 months ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Nov 6, 2024, 4:05 PM EST - 9 months ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Oct 1, 2024, 8:00 AM EDT - 10 months ago

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Sep 30, 2024, 8:00 AM EDT - 10 months ago

Aligos Therapeutics to Present at Investor Conferences in October

Sep 19, 2024, 8:00 AM EDT - 11 months ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Sep 18, 2024, 5:00 PM EDT - 11 months ago

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Aug 15, 2024, 9:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Reverse Stock Split

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Strengthens Board with Two New Independent Directors

Jul 22, 2024, 9:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

May 22, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

May 21, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

Apr 30, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Mar 5, 2024, 4:05 PM EST - 1 year ago

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

Feb 26, 2024, 8:00 AM EST - 1 year ago

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

Feb 20, 2024, 8:00 AM EST - 1 year ago

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

Dec 7, 2023, 4:05 PM EST - 1 year ago

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

Nov 20, 2023, 4:05 PM EST - 1 year ago

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

Nov 13, 2023, 8:00 AM EST - 1 year ago

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

Nov 10, 2023, 8:05 AM EST - 1 year ago

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

Nov 3, 2023, 4:30 PM EDT - 1 year ago

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Announces $92 Million Private Placement Financing

Oct 3, 2023, 7:30 AM EDT - 1 year ago

Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558

Sep 21, 2023, 7:30 AM EDT - 2 years ago

Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009

Jul 19, 2023, 7:30 AM EDT - 2 years ago

Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009

Jun 21, 2023, 4:30 PM EDT - 2 years ago

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Jun 7, 2023, 7:30 AM EDT - 2 years ago

Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

May 24, 2023, 5:26 PM EDT - 2 years ago

Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference

May 12, 2023, 5:05 PM EDT - 2 years ago

Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos' Oligonucleotide Platform for the Treatment of Liver Diseases

May 4, 2023, 4:05 PM EDT - 2 years ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results

Apr 27, 2023, 4:05 PM EDT - 2 years ago

Aligos Therapeutics to Announce First Quarter Results on May 4, 2023

Apr 11, 2023, 6:50 PM EDT - 2 years ago

Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Buyhighsellatlow Jul. 31 at 5:55 PM

If you believe in the potential for $ALGS here at the 50 day is a good add for me.

1 · Reply

Buyhighsellatlow Jul. 30 at 12:57 AM

$ALGS Lost almost $1K on this today. 6M shares outstanding, 62% owned by institutions, 130m cash, 55M mkt cap, enough until mid-2026, phase 2 drugs, collaboration deal with $MRK 🤦

0 · Reply

beeny Jul. 26 at 3:37 PM

$ALGS doubled it you bought around the low👈👀

0 · Reply

Buyhighsellatlow Jul. 24 at 5:09 PM

$ALGS

0 · Reply

Quantumup Jul. 22 at 12:10 PM

0 · Reply

beeny Jul. 17 at 2:30 PM

$ALGS this second half will be vertical ⬆️

0 · Reply

Paddy444 Jul. 17 at 2:11 PM

$ALGS

0 · Reply

Bojack_money Jul. 17 at 1:05 PM

$ALGS Higher highs, higher lows...something something making money.

0 · Reply

HedgeUrHedge Jul. 10 at 4:27 PM

2 · Reply

HedgeUrHedge Jul. 10 at 4:22 PM

1 · Reply

HedgeUrHedge Jul. 8 at 3:10 PM

$ALGS

0 · Reply

HedgeUrHedge Jul. 8 at 3:00 PM

$ALGS bearish sentiment my ass lol. Is stocktwits purposefully suppressing bullish sentiment or is their algorithm inaccurate?

0 · Reply

Bojack_money Jul. 8 at 1:29 PM

$ALGS Let's go! BojackMoney is on the Aligos bandwagon.

0 · Reply

Rasto2020 Jul. 7 at 12:42 AM

$ALGS I like it

0 · Reply

Quantumup Jul. 2 at 12:09 PM

Citizens reit $MDGL MKT-OP/470: "Madrigal ( $MDGL, MO, $470 PT) will deliver a podium presentation highlighting a comparative meta-analysis of glucagon receptor agonists vs. Rezdiffra in MASLD and MASH during the "The Evolving Landscape of MASLD: From Pathophysiology to Therapeutic Innovations" session on Saturday, July 12. Rezdiffra will be highlighted in two posters, which will discuss meta-analyses comparing its efficacy to AkeroanIs ( $AKRO, NC) FGF21 efruxifermin, along with a systemic review of Rezdiffra's randomized controlled trials. The U.S. Rezdiffra launch continues to exceed expectations, with >17K patients on drug as of last quarter and sales handily beating consensus (our coverage here). MDGL is also gearing up for its EU launch, with a regulatory decision anticipated in August. Data recently presented at EASL for Rezdiffra and efruxifermin in compensated cirrhotics showed promise (our coverage here), and we look forward to the comparative analysis in MASH." $IVA $VKTX $ALGS

1 · Reply